

Scientific Program – Details

SESSION 1 Thursday 15 October 2009 (Afternoon)

TOPIC 1 (13h30 – 15h30)

Clinical application of cancer biomarkers: Blood/Serum-based molecular markers

Chairs: Fred Sweep (EU) & Herbert Fritsche (US)

Gene Methylation Biomarkers for Lung Cancer Risk, Recurrence, and Prognosis
(S. Belinsky)

Serum proteomics in lung cancer
(D. Carbone)

The use of autoantibodies in the early detection of cancer
(C. Chapman)

Clinical relevance of circulating tumor cells (CTC) in primary and metastatic breast cancer
(T. Fehm)

Selected abstract for oral presentation (abs. #82): Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor as biomarkers of mesothelioma
(K. Hollevoet)

TOPIC 2 (16h00 – 18h00)

Clinical application of cancer biomarkers: Tissue-based molecular markers

Chairs: Sabine Tejpar (EU) & Elise Kohn (US)

Prognostic and predictive signatures in breast cancer: Update and future perspectives
(N. Harbeck)

Application of High Resolution Mass Spectrometry for Cancer Biomarker Discovery and Validation
(T. Conrads)

Predictive markers for EGFR targeting therapies
(S. Tejpar)

Clinical application of biomarkers: Discovery, validation and application
(E. Kohn)

Selected abstract for oral presentation (abs. #78): EGFR mutations based on circulating free DNA in the subset of Japanese patients from IRESSA Pan ASia Study, a Phase III study of first-line gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced NSCLC
(N. Yamamoto)

Scientific Program – Details (Cont'd)

<p>SESSION 2 Friday 16 October 2009 (Morning)</p>

TOPIC 3 (08h00 – 10h00)

Ethical, legal and regulatory issues in biomarker research

Chairs: Fatima Cardoso (EU) & John Jessup (US)

Informed consent for future research: how much can/should we ask upfront & afterwards?
(E. Eisenhauer)

Coordinating biological material collection in the context of multinational clinical trials
(G. Thomas)

Biomarker research: The patient perspective
(P. Kim)

Panel discussion with interactive participation of the audience

TOPIC 4 (10h30 – 12h30)

Pharmacogenomics & Pharmacogenetics

Chairs: Godefridus Peters (EU) & Geoffrey Liu (US)

The role of pharmacogenetics and pharmacogenomics in cancer therapy
(G.J. Peters)

Pharmacogenomics in pancreatic cancer
(R. Danesi)

Pharmacogenomics in colon cancer
(H.J. Lenz)

Current challenges in the design and conduct of pharmacogenetic
and pharmacogenomic studies
(G. Liu)

Selected abstract for oral presentation (abs. #62): Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib
(E. Giovannetti)

Scientific Program – Details (Cont'd)

SESSION 3 Friday 16 October 2009 (Afternoon)

TOPIC 5 (13h30 – 15h30)

New assessment criteria for clinico-genomic trials

Chairs: Roger Stupp (EU) & Larry Rubinstein (US)

Molecular imaging
(P. Flamen)

Methodology and design of phase 0 and phase 2 trials
with biomarker variables and endpoints
(L. Rubinstein)

Validation of statistically reliable biomarkers
(M. Buyse)

New targets and cancer therapy: successes and failures
(J. Dancey)

TOPIC 6 (16h00 – 18h00)

Can we obtain the most from the least tissue?

Chairs: Manfred Schmitt (EU) & David Rimm (US)

Getting the most from the least tissue
(P. Mack)

Beyond IHC: Accurate, reproducible and quantitative measurement of protein analyte concentrations in
fixed tissue
(D. Rimm)

Optimizing Information Obtained from Fine Needle Aspiration (FNA) Biopsies
(D. Clark)

Emerging tissue-based cancer biomarkers in breast cancer
(M. Schmitt)

Selected abstract for oral presentation (abs. #125): Downregulation of EZH2 is associated with estrogen
receptor upregulation and favourable outcome to tamoxifen in
advanced breast cancer
(E. Reijm)

Scientific Program – Details (Cont'd)

<p>SESSION 4 Saturday 17 October 2009 (Morning)</p>

TOPIC 7 (8h00 – 10h00)

Cancer stem cells: ready for the clinic?

Chairs: Maria Grazia Daidone (EU) & Catherine O'Brien (CA)

BMP4 and the inhibitors of differentiation, Id-1 and Id-3, play an essential role in the maintenance of colon cancer-initiating cells
(C. O'Brien)

Cancer stem cells and the microenvironment: The role of hypoxia
(J. Rich)

Leukemic stem cells
(D. Bonnet)

Stem cells and breast cancer: treatment resistance, markers and novel therapeutic targets
(R. Clarke)

TOPIC 8 (10h30 – 12h30)

Successful clinico-genomic trials: How to run them?

Chairs: Nadia Harbeck (EU) & Bruce Johnson (US)

Ongoing clinical-genomic trials: NNBC3 Europe - Evaluation of the ASCO recommended prognostic factors uPA/PAI-1 in node negative breast cancer patients
(C. Thomssen)

Ongoing clinical-genomic trials: MINDACT
(F. Cardoso)

Ongoing clinical-genomic trials: TAILORx
(M. Mooney)

Targeted therapies directed against EML4-ALK translocations and BRAF mutations in patients with lung cancer
(B. Johnson)

PET imaging in upper GI Cancer - past experience and current EORTC Initiatives
(F. Lordick)